A Mapping Review on the Uptake of the COVID-19 Vaccine among Adults in Africa Using the 5As Vaccine Taxonomy

Michael E. Kalu,1,2,a Oluwagbemiga Oyinola,1,3 Michael C. Ikebaku,1,4 Israel I. Adandom,1,5 Anthony O. Iwuagwu,1,6 Chigozie J. Ezulike,1,6,7 Ernest C. Nwachukwu,1,8 and Ekezie Uduonu1,9

1Emerging Researchers and Professionals in Ageing-African Network, Hamilton, Ontario, Canada; 2School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada; 3Medical Social Services Department, University College Hospital Ibadan, Ibadan, Nigeria; 4University of Benin Teaching Hospital, Benin, Nigeria; 5Cedarcrest Hospitals, FCT-Abuja, Nigeria; 6Department of Social Work, University of Nigeria, Nsukka, Nigeria; 7Department of Social and Behavioral Sciences, City University of Hong Kong, Kowloon, Hong Kong; 8Physiotherapy Department, Enugu State University of Science and Technology Teaching Hospital, Parklane-Enugu; 9Department of Medical Rehabilitation, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria, Enugu Campus

Abstract. Uptake of a vaccine is complete if individuals are aware of the associated risks of the vaccine, accept the vaccine, and respond positively to the nudges (activation) to increase the uptake, and respond when the vaccine is made accessible and affordable. We mapped systematically the existing literature concerning the 5As—acceptability, accessibility, affordability, awareness, and activation—of COVID-19 vaccination among adults and, specifically, older adults (55 years and older) in Africa. We searched multiple databases from 2020 to December 2021. Using predefined inclusion and exclusion criteria, two reviewers screened citations, conducted title and abstract screening, and extracted data independently. We included 68 articles conducted in 33 African countries, primarily cross-sectional studies (n = 49, 72%). None of the articles focused on older adults only, but 22 articles (32%) included at least one older adult (55 years and older) in their sample size. Acceptance (n = 58, 85%) was the most commonly researched aspect of vaccine uptake, followed by accessibility (n = 17, 25%), awareness (n = 13, 19%), and affordability (n = 5, 7.0%). We found only one report on activation. Factors affecting acceptance of the COVID-19 vaccine in Africa were grouped into sociodemographic factors; knowledge-, attitude-, and belief-related factors; a COVID-19 vaccine efficacy and safety concern factor; and trust in government and public health authorities. The governments of African nations should focus on strategies to influence the modifiable factors identified in this review. More studies are needed to evaluate the impact of nudges (activation) to improve COVID-19 vaccine uptake in African nations.

INTRODUCTION

Deaths from COVID-19 infection are likely to reduce if we achieve herd immunity—when 60% to 80% of the world population has received the two doses of the COVID-19 vaccine.1 Vaccine hesitancy, defined as a delay in acceptance or refusal of the vaccine even if available, is a growing health issue globally that presents an obstacle to achieving substantial uptake compliance of any new vaccine.2 The determinants of vaccine hesitancy include acceptability, accessibility, affordability, awareness, and activation3; these are the myriad possible root causes of vaccine uptake.3 Vaccine hesitancy results from a complex decision-making process influenced by various environmental, agent, and personal factors.4 Environmental factors include, but are not limited to, public health policies related to the design of vaccination programs, and messages spread by the media; agent factors include the perception of vaccine safety, effectiveness, and disease risk.5 Personal factors include knowledge, previous historical experience, socioeconomic status, and religious belief.6 These factors have been explored in studies on COVID-19 vaccine uptake.5,6 The study by Lin et al.5 included 126 studies in a rapid systematic review and reported 1) declining COVID-19 vaccine acceptance (from > 70% in March to < 50% in October) with demographic, socioeconomic, and partisan divides; and 2) perceived risk, concerns over vaccine safety and effectiveness. Doctor recommendation and inoculation history were common factors that influenced vaccine acceptance. Similarly, Sallam6 included 31 peer-reviewed articles from 33 countries and reported a low rate of COVID-19 vaccine acceptance in the Middle East, Russia, Africa, and several European countries. Two reviews have been conducted to explore the extent and determinants of COVID-19 vaccine hesitancy in South Africa7 and to determine the acceptance rate of the COVID-19 vaccine in Africa.8 Although the findings from the reviews have provided information to guide interventional measures aimed at increasing acceptance, other determinants of vaccine hesitancy, including access, affordability, awareness, and activation, are largely ignored. Therefore, a more comprehensive review is needed to highlight how other determinants have reduced vaccine hesitancy across African nations. Older adults are at a greater risk of contracting and dying from the COVID-19 virus; therefore, our review is situated in the context of the older population in Africa.

Gerontological studies conducted in Africa have chosen ages 50, 55, 60, or 65 as a lower limit to be considered old.9 However, in this article, we define older adults as 55 years and older, because this value aligns with the Africa Centers for Disease Control and Prevention reports.10 Older adults are at a greater risk of contracting and dying from COVID-19 infection. Therefore, older adults and individuals living with multiple chronic conditions should be the first category of individuals to receive the COVID-19 vaccine. Although this is true in developed regions of the world, this is not the case in some African countries. For instance, according to Africa Centers for Disease Control and Prevention, countries such as Nigeria, South Africa, Namibia, and Zimbabwe did not list older adults (50 years and older) as their priority group.10 Reasons for not listing adults 50 years and older as a priority group could include a lack of implementation of health-care
access policies targeted towards older adults or loose policies that cannot guide detailed program health-care access. These reasons are further influenced by the lack of conviction that old-age-related health should be a priority in the context of diverse, pressing public health needs for women and children that currently account for the highest proportion of the population for most African nations. Not placing older adults as a priority group in some African countries adds even more challenges to the already existing issues regarding vaccination, such as accessibility and acceptance. The primary objective of this review was to map the existing literature concerning the 5As—acceptability, accessibility, affordability, awareness, and activation of the COVID-19 vaccination—among adults 55 years and older in Africa. We assumed that studies exploring these concepts among older adults in Africa might not be extensive; therefore, we expanded our search to include adults 18 years and older. Thus, the secondary aim was to map the existing literature across the 5As for adults 18 years and older in Africa. First we describe the current state of the COVID-19 vaccination in Africa. Second, based on our reviewed literature, we explain the current COVID-19 vaccination uptake in Africa using Thomson’s 5As taxonomy. Gaps in the literature to ensure the uptake of COVID-19 vaccination using the 5A taxonomy are provided.

COVID-19 VACCINATION IN AFRICA

As of January 2, 2022, 56.90% of the vaccine supplied has been administered, and 13.65%, 9.11%, and 0.31% of the African population have received one vaccine, two vaccines, and the booster dose of the COVID-19 vaccine, respectively. According to Africa Centers for Disease Control and Prevention vaccine dashboard, all African countries have received the COVID-19 vaccine and commenced vaccination except for Eritrea. Twenty countries have fully vaccinated at least 10% of their population (Figure 1); other African countries not shown in Figure 1 have less than 10% of their population fully or partially vaccinated. Several countries received vaccines from COVID-19 Vaccine Global Access (COVAX) (50 countries), African Union’s COVID-19 Africa Vaccine Acquisition Task Team (AVATT) (38 countries), and both (50 countries). COVID-19 vaccine types currently administered in African countries are AstraZeneca, Sinopharm, Sputnik V, BioNTech, Sinovac, Moderna, and Covaxin.

Across African countries, the priority groups to receive the COVID-19 vaccine include health-care workers, people with chronic conditions, people 50 years and older, front-line/essential workers, and leaders/prisoners. Although health-care workers were consistently a priority group to receive the COVID-19 vaccine, people 50 years and older were not among the priority group in some African countries, including South Africa, Zimbabwe, Nigeria, Botswana, Mozambique, Angola, and Cameroon. Not including the older adult population is a concern for several reasons. First, older adults inherently have compromised immunity as a result of accumulated health disadvantages across their life course. Second, most older adults in Africa reside in rural areas with little or no access to health-care facilities and, by extension, no access to the COVID-19 vaccine. The percentage of adults 55 years and older across the 22 countries with at least 10% of their population fully or partially vaccinated is presented in Figure 2.

Based on the definitions of Thomson et al., accessibility is a country’s/individual’s ability to obtain a vaccine within a reasonable reach, whereas affordability is defined as economic accessibility (i.e., a country/individual can pay for vaccines with minimal financial and non-financial cost [e.g., time]). Awareness is the degree to which individuals know the need for and availability of recommended vaccines, and their associated risks and benefits. Although acceptance is the degree to which individuals recognize or agree to take and/or question a vaccine, activation is the extent to which individuals are nudged toward vaccine uptake.
Among the 5As of acceptability, accessibility, affordability, awareness, and activation, activation is rarely discussed among scholars or even in African countries’ media outlets. Although acceptance, access, and affordability are often discussed, culturally motivated awareness programs that are age friendly are rare. Therefore, we reviewed the literature systematically to describe how many studies have explored each component of the 5As with regard to COVID-19 vaccination among the older adult population in Africa.

METHODS

We followed Grant and Booth’s description of mapping review to categorize existing literature from which to commission further reviews and/or primary research by identifying gaps in the literature. We identified literature of aging and mapped the existing literature across the 5As: acceptability, accessibility, affordability, awareness, and activation.

Search. We did a preliminary search in the Cumulative Index to Nursing and Allied Health Literature (CINAHL) including aging terms such as aging, older adults, older people, and other search terms described later. This search yielded no articles. We repeated the exact search in PubMed, using the COVID-19 vaccine filter “treatment and prevention,” and 230 articles were identified. None of these articles focused on vaccine uptake among older adults in Africa. We chose CINAHL and PubMed for our preliminary search because of their extensive index citations and a recommendation of them as being comprehensive databases for reviews. We repeated our search removing the aging terms and examined the databases PubMed and Ovid (EMBASE, CINAHL, and PsychINFO) from 2020 to December 2021 (see Table 1 for our search strategy).

Study selection. All citations from each database were exported into Rayyan Qatar Computing Research Institute (QCRI). After removing duplicates, studies were conducted in two stages: title/abstract and full-text screening. Two raters performed a pilot test independently, which consisted of a title/abstract and full-text screening of the first 50 articles using predefined inclusion and exclusion criteria to determine interrater reliability. Light’s kappa of the raters for both title/abstract and full-text screening were 0.88 and 0.92. These kappa values indicate an almost perfect strength of agreement; thus, retrieved articles were divided among the two raters. Questions, concerns, and disagreements at any stage were discussed during research meetings. We included articles focused on the concepts related to COVID-19 vaccine uptake as guided by the 5As by Thomas et al. There was no restriction on the type of study design; quantitative, qualitative, and mixed-method studies were included. Because of the limited number of articles in this

| Major term | Term |
|------------|------|
| Vaccine uptake | Accessibility or obtainability or gain access or availability or location or convenience or affordability or awareness or acceptance or activation or cost or economical or vaccine uptake |
| COVID-19 | Egypt or Morocco or Tunisia or Algeria or Libya or Somalia or Mali or Angola or Ethiopia or Nigeria or Niger or Benin or Gabon or Botswana or The Gambia, or Rwanda or Burkina Faso or Ghana or Sao Tome and Principe or Burundi or Guinea or Senegal or Cabo Verde or Guinea-Bissau or Seychelles or Cameroon or Kenya or Sierra Leone or Central African Republic or Lesotho or Somalia or Chad or Liberia or South Africa or Comoros or Madagascar or South Sudan or Congo, Dem. Rep. or Malawi or Sudan or Congo, Rep or Mali or Tanzania or Cote d’Ivoire or Mauritania or Togo or Equatorial Guinea or Mauritius or Uganda or Eritrea or Mozambique or Zambia or Eswatini or Namibia or Zimbabwe |
| African country | |
subject area, we included opinions and editorials that discussed ideas regarding COVID-19 vaccine uptake among older adults in Africa. We searched the included articles, the African Journals Online portal,19 WHO websites,20 the African Union Center for Disease Control and Prevention,10 and country-specific centers for disease control, such as the Nigeria Center for Disease Control21 and the South Africa Department of Health.22

Articles were excluded if the study population or discussion did not focus on Africans and were not published in English or French.

Data extraction. We adopted a standardized data extraction sheet used in a previous scoping review23 to extract data from the included studies. We “pilot-tested” the data extraction process in a research meeting. Two reviewers extracted the authors’ names; the country in which the study was conducted; study aims, research question(s), and hypotheses; study setting; type of study (qualitative, quantitative, mixed method, editorials, and gray literature); study hypotheses; study setting; type of study (qualitative, quantitative, mixed method, editorials, and gray literature); study design; sampling method; participant characteristics (e.g., number of participants, mean age of the participants); main study findings; and recommendations (policy, practice, and research).

Collating, summarizing, and reporting the results. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart to describe the process of data selection. The best-fit framework synthesis guided the grouping of the included studies.24 This approach allowed us to map the studies across the 5As: acceptability, accessibility, affordability, awareness, and activation. Two authors read the included studies and mapped them independently across the 5As, noting those articles that did not apply. Both authors met and discussed their mapping; discrepancies were discussed in a research team meeting.

RESULT

We retrieved 3,556 studies from our database search. After removing duplicates, 3,431 citations underwent abstract and title screening, which resulted in the exclusion of 2,546 studies. The remaining 885 studies underwent full-text screening; we included 53 studies. An additional 15 studies from hand-searching included studies, African journals, and websites, resulting in 68 articles (Figure 3).

Description of included studies. The 68 articles included in this review are presented in Supplemental Table S1. Included articles/reports were from 33 African countries (Figure 4): from one single African country (n = 49, 72%), multiple African countries (n = 11, 16%),25–36 or no specific African country (n = 8, 12%).37–44 Almost three quarters of the included articles were cross-sectional studies (n = 50, 74%), whereas the remaining were mixed method (n = 4, 6%) and opinion papers or commentaries (n = 14, 20%). None of the articles focused on older adults only, but 22 (32%) studies included adults 55 years and older in their sample size. Among the cross-sectional and mixed-methods studies (n = 54, 79%), most surveyed the general population (n = 34, 63%), followed by health-care workers (n = 13, 24%) and specific populations (n = 7, 12%), such as people living with HIV,45–47 pregnant women,46,47 adult caregivers,48 and medical students.39–51

Mapping the existing literature across Thomas’s 5As.

Close to three quarters of the included reports (n = 43, 63%) focused only on acceptance (n = 49) or accessibility (n = 4) of the COVID-19 vaccine. The remaining 25 reports focused on at least two of the 5As.

Acceptance. Fifty-eight articles reported on acceptance, with acceptance percentages of COVID-19 vaccine ranging from 15.4%52 to 90%.31 Among the 58 articles, nine studies reported ≥ 80%26,27,31,32,36,53–56 of their participants would accept/take the COVID-19 vaccine when available, 27 studies reported between 50% and 79%28–30,34–36,46,47,51,57–73 and 15 studies reported < 50%.36,45,49,50,52,74–82

Of 58 studies, 31 reported factors that influence the desire to be vaccinated and were grouped as 1) sociodemographic factors, including gender (male45,49,50,60,64,67,69,70,80–83 or female75), age (old age [55 years and older],75,83 middle age [34–41 years],46,69 and younger age [18–20 years]25,34,34,64,65), marital status,49,64,75 higher educational status,25,34,64 higher income,25,45,46,50,61 occupation,59,75 higher education,25,44,75,83,84 religion and rural residence64,75; 2) knowledge-, attitude-, and belief-related factors, including COVID-19 knowledge of prevention practices and the vaccine,27,45,46,50,61 lack of adequate information (related to conspiracy theories),58,66,79,81 and how attitude/belief influences vaccine willingness to take the COVID-19 vaccine55,57,59,66,70,79,79,79; 3) efficacy and safety concerns, including concern over safety/ side effects of the vaccine25,27,55,58,67,74,79,92 or doubts about vaccine effectiveness27,55,58,67,74,79,92 and 4) others, including the desire to protect oneself or others,59,77 a perception of being at low risk,69,80 previous history of vaccination as a child,91 lack of direct patient contact,92 working in rural areas,86 trust in government and public health authorities, and willingness to pay for and travel to get a COVID-19 vaccine.83

Accessibility. Sixteen articles that discussed access to the COVID-19 vaccine in Africa were based on 1) location, which was described as the distance to and from COVID-19 vaccination centers30,35,37,38,42,85; 2) factors that could promote access to the COVID-19 vaccine, including developing African-focused coordination44,86 or international cooperation41,87,88 for the distribution of the COVID-19 vaccine, and vaccine confidence89,90; 3) government-related factors, such as refusal to provide the COVID-19 vaccine despite international aid,91 inequitable distribution of the COVID-19 vaccine,29,30,42 and general accessibility issues.53,73,90

Affordability. Five reports (four opinion papers37,44,85,86 and one cross-sectional study73) discussed the affordability of the COVID-19 vaccine in Africa. Although Afolabi and Ilesanmi85 highlighted the COVAX program as a viable strategy for low-income countries in Africa that may not have the funds to purchase the COVID-19 vaccine, Acharya et al.37 elucidated that low socioeconomic status can affect vaccine purchase, resulting in an inequitable distribution of the COVID-19 vaccine.29,30,42 and general accessibility issues.53,73,90

Awareness. Thirteen articles reported on awareness of the COVID-19 vaccine, of which only four assess participant knowledge. Participant knowledge of the COVID-19 vaccine
varies: 98%62 and 67%73 in a Nigerian population, and 74%57 and 53%66 in an Ethiopian population. Other authors focused on describing how information concerning COVID-19 vaccine efficacy and side effects should be made known to the populace25,38,41,49,71,75,85or how knowledge of the COVID-19 vaccine could influence willingness to accept the COVID-19 vaccine.28,78

**Activation.** One study noted that participants were nudged toward using protective measures against the COVID-19 virus rather than getting the COVID-19 vaccine.79

**DISCUSSION**

We initially set out to map literature concerning the 5As—acceptability, accessibility, affordability, awareness, and activation of the COVID-19 vaccine—among older adults in the African region. No article explored any of the 5As for older adults alone; however, 38% of the studies included older adults (55 years and older) in their sample size. Older adults are at a greater risk of contracting and dying from the COVID-19 virus; therefore, most governments of African nations, especially those with an increasing number of older adults (e.g., Nigeria and South Africa), should revisit their priority list. Furthermore, studies exploring factors and determinants of vaccine hesitancy among older adults in Africa are warranted. Interestingly, the 5C scale of the Betsch et al.92 and the Vaccination Attitudes Examination scale93 have shown good internal reliability, and convergent, discriminant, and concurrent validity among the older adult population.

We included 68 articles when we extended our review to reports that explored the 5As among adults 18 years and older. Consistent with the review by Thomas et al.,3 acceptance was the most common research aspect of COVID-19 vaccine uptake among adults in Africa. The ease of accessing acceptance could explain why acceptance is studied frequently among researchers. For instance, most studies assessed acceptance with a single question: Are you willing to take the COVID-19 vaccine when available? Regardless, the success of the COVID-19 vaccination often depends on peoples’ willingness to receive the vaccination. Consistent with previous reviews,94,95 we grouped factors that influence the acceptability of the COVID-19 vaccine into sociodemographic, knowledge related, efficacy, and safety concerns. Factors that could promote access to the COVID-19 vaccine in Africa include international cooperation, vaccine confidence, and government-related factors. This grouping and its specific factors highlight the need for policymakers to focus on modifiable factors that could promote the acceptability and accessibility of the COVID-19 vaccine to promote herd immunity.85 To predict achieving herd immunity of at least 75%,96 longitudinal studies should explore whether the baseline prevalence acceptance rate is a predictor of completing the required COVID-19 vaccine doses, including the booster dose.

Accessibility and affordability are closely related concepts in vaccine uptake. Accessibility, in the context of this view, focused on reasonable reach, defined by distance to and from vaccination centers, whereas affordability refers to economic accessibility. At the individual level, affordability is currently not an issue in the uptake of the COVID-19 vaccine in Africa because individuals are not required to pay for the vaccine. However, different governments in African countries...
purchase the COVID-19 vaccine for their citizens. Interestingly, the COVAX initiative, co-led by the WHO, the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance, promises to offer equitable access to vaccines to low- and middle-income countries through a highly subsidized price. Currently, we are not aware of where individuals are being asked to pay for the COVID-19 vaccine in Africa. Although the direct cost of the COVID-19 vaccine is being borne by the governments of African countries, Illesanmi et al. surveyed 440 participants in Nigeria to describe their willingness to pay for the COVID-19 vaccine. They reported that 81 respondents (18.40%) were willing to pay for the COVID-19 vaccine because of their need to stay healthy. Of these individuals willing to pay, 45 (55.6%) were willing to pay at least 5,000 NGN ($US13.16). This study provided a glimpse into people's willingness to pay for the vaccine. In some African countries, residents/citizens do not have access to the health services they need, when and where they need them, without incurring financial hardship. Therefore, residents/citizens pay for health-care services. Although the COVID-19 vaccine has been shown to induce a robust immune response toward the virus, its duration is still inconclusive. However, studies have reported that waning of neutralizing antibody levels occurs ~6 months post-vaccination. With so many unknowns about the virus and its continuous mutations, it is plausible that several booster shots will be required. Therefore, the African nations' governments may have limited funding to continue purchasing the vaccine; they may ask citizens to pay for it. The international community should rethink the approach to ensure the sustainability of initiatives to ensure free access to the COVID-19 vaccine in the global south.
That notwithstanding, indirect costs hinder COVID-19 vaccine uptake in most African nations, such as transportation expenses to the health facility and loss of productive hours during the vaccination wait time. The governments of African nations should discuss these salient indirect costs and how to alleviate them, because resolution of these issues may improve COVID-19 vaccine uptake, especially among vulnerable groups, which includes older adults residing in the rural areas. We suggest that governments transport the vaccine to the rural communities if possible, or collaborate with nongovernmental organizations to subsidize or provide free transportation to vaccination centers. Several policies and strategies, including the “reaching every district approach” and the “door-to-door massive vaccination campaign,” have proved to increase vaccination in some African nations. The governments of African nations can consider whether these approaches could increase COVID-19 vaccine uptake because the structures exist in most health-care services.

Consistent with the previous review, activation, as defined earlier, is the extent to which individuals are nudged toward vaccine uptake, and is rarely studied in the literature. We found only one study that reported that participants were nudged toward using protective measures against the COVID-19 virus rather than acquiring the vaccine. Typical examples of nudges describing choice options are warnings/graphics, reminders, precommitment, and feedback. The use of pictures (as a warning) or reminders to depict the benefits of getting the COVID-19 vaccine, and the implications of not getting the vaccine could improve uptake. For instance, to increase social connectedness during the nationwide lockdown, we (the Emerging Researchers & Professionals in Ageing–African Network; https://erpaan.org/) created a visible paper reminder called “Connect with Parents Reminder Signage” placed at various clinics. This reminder helped clinicians prompt their patients to connect with their parents and grandparents in Nigeria socially through telephone. This approach is a typical example of a reminder as a nudge. The governments of African nations can apply similar concepts to increase COVID-19 vaccine uptake among older adults in Africa. For instance, nationwide signage called “Remind Your Parents and Grandparent to Get the COVID-19 Vaccine” should be launched in strategic areas in the cities. This approach is promising, because it was successful when we applied a similar approach during the nationwide lockdown in Nigeria. This simple and cost-effective approach to nudging individuals to get the COVID-19 vaccine can be implemented easily across various health clinics, because individuals will more likely get the vaccine when recommended by their health-care professionals.

Although this review mapped out the literature concerning the 5As of COVID-19 vaccination, there are limitations. Because some of the national journals in Africa are not indexed in MEDLINE or related databases, we may have missed some studies. Furthermore, including articles published in English and French only may have led to missing some articles/reports. The mapping review only provides a surface-level description and lacks a critical and robust analysis of concepts explored. However, our study highlighted how concepts, including acceptability, accessibility, affordability, awareness, and activation relating to COVID-19 vaccine uptake, are explored in the African context. Because of the ambiguity and possible overlap of the 5As, we may have mis-mapped some articles. As suggested by Thomas et al., the use of the 5A is for a practical purpose: to facilitate classification and easy identification of factors influencing vaccine uptake. Therefore, readers should reflect on this when interpreting the findings of this review.

Currently, no published evidence explores acceptability, accessibility, affordability, awareness, and activation of COVID-19 vaccine uptake among the older adult (⩾55 years) population in Africa. Although 68 articles explored these concepts across adults (⩾18 years) in Africa, acceptability was studied primarily, with activation rarely studied. We grouped factors affecting acceptability into sociodemographic factors; knowledge-, attitude-, and belief-related factors; COVID-19 vaccine efficacy and safety concerns; and trust in government and public health authorities.

Received May 7, 2021. Accepted for publication March 14, 2022.
Published online May 9, 2022.

Note: A supplemental table appears at www.ajtmh.org.

Acknowledgments: We acknowledge the members of Emerging Researchers & Professionals in Ageing–African Network for proofing this manuscript. The American Society of Tropical Medicine and Hygiene has waived the open-access fee for this article due to the ongoing COVID-19 pandemic and has assisted with publication expenses.

Authors’ addresses: Michael E. Kalu, Emerging Researchers and Professionals in Ageing–African Network and School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada, E-mail: kalum@mcmaster.ca. Oluwagbemiga Oyinlola, Emerging Researchers and Professionals in Ageing–African Network and 3Medical Social Services Department, University College Hospital, Ibadan, E-mail: gsticks2@gmail.com. Michael C. Ibekaku, Emerging Researchers and Professionals in Ageing–African Network and University of Benin Teaching Hospital, Benin, Nigeria, E-mail: michael.ibekaku.192311@unn.edu.ng. Israel A. Adandom, Emerging Researchers and Professionals in Ageing–African Network and Cedarcrest Hospitals, FCT-Abuja, Nigeria, E-mail: israeladandom@gmail.com. Anthony O. Iwuagwu, Emerging Researchers and Professionals in Ageing–African Network and Department of Social Work, University of Nigeria, Nsukka, Nigeria, E-mail: anthony.iwuagwu@unn.edu.ng. Chigozie J. Ezulike, Medical Social Services Department, University College Hospital Ibadan, Ibadan, Nigeria, E-mail: julietezulike@gmail.com. Ernest C. Nwachukwu, Emerging Researchers and Professionals in Ageing–African Network and Physiotherapy Department, Enugu State University of Science and Technology Teaching Hospital, Parklane-Enugu, E-mail: ernest.nwachukwu.196200@unn.edu.ng. Ekezie Udouon, Emerging Researchers and Professionals in Ageing–African Network and Department of Medical Rehabilitation, Faculty of Health Sciences and Technology, College of Medicine, University of Nigeria, Enugu Campus, E-mail: ekezie.udouon@unn.edu.ng.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES
1. World Health Organization, 2020. Episode #: herd immunity. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/science-in-5/episode-1. Accessed April 2, 2022.
2. Larson HJ et al., 2015. Measuring vaccine hesitancy: the development of a survey tool. Vaccine 33:4165–4175.
3. Thomson A, Robinson K, Vallée-Tourangeau G, 2016. The 5As: a practical taxonomy for the determinants of vaccine uptake. Vaccine 34:1018–1024.
4. MacDonald NE et al., 2015. Vaccine hesitancy: definition, scope and determinants. Vaccine 33:4161–4164.
5. Sallam M, 2021. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines 9: 1–14.
6. Lin C, Tu P, Beltch LM, 2021. Confidence and receptivity for covid-19 vaccines: a rapid systematic review. Vaccines (Basel) 9: 1–32.
7. Cooper S, van Rooyen H, Wiysonge CS, 2021. COVID-19 vaccine hesitancy in South Africa: how can we maximize uptake of COVID-19 vaccines?. Expert Review of Vaccines 20: 921–933.
8. Wake AD, 2021. The acceptance rate toward COVID-19 vaccine in Africa: a systematic review and meta-analysis. Glob Pediatr Health 8: 1–13.
9. Velkoff VA, Kowal PR, 2006. Aging in Sub-Saharan Africa: The Changing Demography of the Region. Available at: https://www.ncbi.nlm.nih.gov/books/NBK20301/. Accessed July 2, 2021.
10. Africa’s Centers for Disease Control and Prevention, 2021. Coronavirus Disease 2019 (COVID-19) – Africa CDC. Available at: https://africacdc.org/covid-19/. Accessed April 2, 2022.
11. Aboderin JB, 2014. Older people’s health in sub-Saharan Africa. Lancet 285: E9–E11.
12. Saka S, Oosthuizen F, Nlooto M, 2019. National policies and practices to improve uptake of COVID-19 vaccine in Africa: a systematic review. J Glob Health 11: 1–14.
13. Our World in Data, 2022. Coronavirus (COVID-19) Vaccinations. Available at: https://ourworldindata.org/covid-vaccinations. Accessed April 2, 2022.
14. Grant MJ, Booth A, 2009. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J 26: 91–108.
15. Gusenbauer M, Haddaway NR, 2020. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. Res Synth Methods 11: 181–217.
16. Kalu ME, 2019. Setting priorities for ageing research in Africa: a systematic mapping review of 512 studies from sub-Saharan Africa. J Glob Health 11: 1–14.
17. Landis JR, Koch GG, 1977. The measurement of observer agreement for categorical data. Biometrics 33: 159–174.
18. Ginsburg GS, 2005. DNA microarrays in clinical medicine. JAMA 293: 2451–2457.
19. World Health Organization, 2021. Strategic Response to COVID-19 in the WHO African Region | WHO | Regional Office for Africa. Available at: https://www.afro.who.int/publications/strategic-response-covid-19-who-african-region. Accessed February 18, 2022.
20. Nigerian Center for Disease Control, n.d. NCDC Coronavirus COVID-19 Microsite. Available at: https://covid19.ncdc.gov.ng/#. Accessed February 18, 2022.
21. South Africa Department of Health, n.d. COVID-19 Online Resource & News Portal. Available at: https://sacoronavirus.co.za/. Accessed April 2, 2022.
22. Kalu ME, Maximos M, Sengiad S, Dal Bello-Haas V, 2019. The role of rehabilitation professionals in care transitions for older adults: a scoping review. Phys Occup Ther Geriatr 37: 123–150.
23. Carroll C, Booth A, Leaviss J, Rick J, 2013. “Best fit” framework synthesis: refining the method. BMC Med Res Methodol 13: 1–16.
24. Solis Arce JS et al., 2021. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med 27: 1385–1394.
25. Solis Arce JS et al., 2021. COVID-19 vaccine acceptance and hesitancy in low and middle income countries, and implications for messaging. medRxiv. doi: 10.1101/2021.03.11.21253419.
26. Bono SA et al., 2021. Factors affecting COVID-19 vaccine acceptance: an international survey among low- and middle-income countries. Vaccines (Basel) 9: 515.
27. Faezi N et al., 2021. Peoples’ attitude toward COVID-19 vaccine acceptance, and social trust among African and Middle East countries. Health Promot Perspect 11: 171–178.
28. IPSOS, 2020. Three in Four Adults Globally Say They Would Get a Vaccine for COVID-19. Available at: https://www.ipsos.com/en/three-four-adults-globally-say-theyd-get-vaccine-covid-19. Accessed January 3, 2022.
29. IPSOS, 2020. COVID-19 Vaccination Intent Is Decreasing Globally. Available at: https://www.ipsos.com/en/global-attitudes-covid-19-vaccine-october-2020. Accessed January 3, 2022.
30. Kanyanda S, Markhof Y, Wollburg P, Zeeza A, 2021. The acceptance of COVID-19 vaccines in sub-Saharan Africa: evidence from 6 national phone surveys. medRxiv. Available at: https://bmjopen.bmj.com/content/11/12/e055159. Accessed January 3, 2022.
31. Lazarus JV et al., 2021. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 27: 225–228.
32. Turnbull AE et al., 2018. A survey of Delphi panelists after core outcome set development revealed positive feedback and methods to facilitate panel member participation. J Clin Epidemiol 102: 99–106.
33. Lazarus JV et al., 2020. Hesitant or not? The association of age, gender, and education with potential acceptance of a COVID-19 vaccine: a country-level analysis. J Health Commun 25: 799–807.
34. Africa Centres for Disease Control and Prevention, London School of Hygiene and Tropical Medicine’s Vaccine Confidence Project, 2021. 2021 COVID-19 Vaccine Perceptions: A 15-Country Study. Available at: https://africareddc.org/download/covid-19-vaccine-perceptions-a-15-country-study/. Accessed January 3, 2022.
35. Manann KA, Farhana KM, 2020. Knowledge, attitude and acceptance of a COVID-19 Vaccine: A Global Cross-Sectional Study Int J Bus Soc Sci 6: 1–10.
36. Acharya KP, Ghimire TR, Subramanya SH, 2021. Access to and equitable distribution of COVID-19 vaccine in low-income countries. Vaccines 6: 1–3.
37. Africa Centres for Disease Control and Prevention, 2020. Majority of Africans Would Take a Safe and Effective COVID-19 Vaccine. Available at: https://africareddc.org/news-item/majority-of-africans-would-take-a-safe-and-effective-covid-19-vaccine/. Accessed January 3, 2022.
38. Ekwebelem OC, Yunusa I, Onyeaka H, Ekwebelem NC, Nnorom-Dike O, 2021. COVID-19 vaccine rollout: will it affect the rates of vaccine hesitancy in Africa? Public Health 197: e18–e19.
39. IPSOS, 2020. U.S. and U.K. Are Optimistic Indicators for COVID-19 Vaccination Uptake. Available at: https://www.ipsos.com/en-global-attitudes-covid-19-vaccine-december-2020. Accessed January 3, 2022.
40. Jerving S, 2021. The long road ahead for COVID-19 vaccination in Africa. Lancet 398: 827–828.
41. Masinga Loembé M, Nkengasong JN, 2021. COVID-19 vaccine access in Africa: global distribution, vaccine platforms, and challenges ahead. BMC Med 20: 1383–1390.
42. Machingaidze S, Wiysonge CS, 2021. Understanding COVID-19 vaccine hesitancy. Nat Med 27: 1338–1339.
43. Nkengasong JN, Ndembí N, Tsanghela A, Raji T, 2020. COVID-19 vaccines: how to ensure Africa has access. Nature 586: 197–199.
44. Meslin Y, Aragaw M, Geze S, Tefera BT, 2021. Factors associated with intention to receive COVID-19 vaccine among HIV positive patients attending ART clinic in southwest Ethiopia. Patient Prefer Adherence 15: 2391–2395.
45. Hoque AM, Buckus S, Hoque M, Hoque ME, Van Hal G, 2020. COVID-19 vaccine acceptability among pregnant women at a primary health care facility in Durban, South Africa. Eur J Med Heal Sci 2: 1–6.
46. Carcelen AC et al., 2022. COVID-19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19 vaccination rollout in sub-Saharan Africa. Hum Vac Immun 18: 1–6.
47. Kanyike AM et al., 2021. Acceptance of the coronavirus disease-2019 vaccine among medical students in Uganda. Trop Med Health 49: 1–11.
50. Ngoyi JM, Mbuyu K, Kibwe D, 2020. Covid-19 vaccination acceptance among students of the higher institute of medical techniques of Lubumbashi, Democratic Republic of Congo. Rev Influen 4: 48–52.
51. Saied SM, Saied EM, Kabbash IA, Abd SAEF, 2021. Vaccine hesitancy: beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students. J Med Virol 93: 4280–4291.
52. Dinga JN, Sindia LK, Titanji VPK, Diclemente J, 2021. Assessment of vaccine hesitancy to a COVID-19 vaccine in Cameroonian adults and its global implications. Vaccines 9: 1–15.
53. Adeniyi OV, Stad D, Singata-Madliki M, et al., 2021. Acceptance of COVID-19 vaccine among the healthcare workers in the Eastern Cape, South Africa: a cross sectional study. Vaccines 9: 666.
54. Oyekale AS, 2021. Willingness to take COVID-19 vaccines in Ethiopia: an instrumental variable probit approach. Int J Environ Res Public Health 18: 8892.
55. Bereket AG et al., 2021. Healthcare workers attitude towards SARS-COV-2 vaccine, Ethiopia. Glob J Infect Dis Clin Res 7: 43–48.
56. Dereje N et al., 2021. COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: a mixed-methods study. medRxiv. doi: 10.1101/2021.02.25.21252443.
57. Abebe H, Shitru S, Mose A, 2021. Understanding of COVID-19 vaccine knowledge, attitude, acceptance, and determinants of COVID-19 vaccine acceptance among adult population in Ethiopia. Infect Drug Resist 14: 2015–2025.
58. Botwe BO, Antwi WK, Adusei JA, Mayeden RN, Akudjedu TN, Sule SD, 2021. COVID-19 vaccine hesitancy concerns: findings from a Ghana clinical radiography workforce survey. Radiography. 28: 537–544.
59. Khalis M et al., 2021. Acceptability of COVID-19 vaccination among health care workers: a cross-sectional survey. Available from Research Square (non-peer reviewed), doi: 10.21203/rs.3.rs-745232/v1.
60. Khairy A et al., 2021. Acceptability of COVID-19 vaccination among healthcare workers in Sudan: a cross sectional survey. Available from Research Square (non-peer reviewed), doi: 10.21203/rs.3.rs-745232/v1.
61. Kollamparambil U, Oyenubi A, Nwosu C, 2021. COVID19 vaccine intentions in South Africa: health communication strategy to address vaccine hesitancy. BMC Public Health 21: 1–12.
62. Paschal Chiedziozi A et al., 2021. Willingness to accept a potential COVID-19 vaccine in Nigeria. Am J Med Sci Med 9: 1–5.
63. Ditekemena JD, Nkamba DM, Mutwadi A, et al., 2021. COVID-19 vaccine acceptance in the Democratic Republic of Congo: a cross-sectional survey. Vaccines 9: 153.
64. Echoru I, Ajambo PD, Keirania E, Bukena EEM, 2021. Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda. BMC Public Health 21: 1–10.
65. Mcbbee L, Tapera O, Kanyangarara M, Barattucci M, 2021. Factors associated with COVID-19 vaccine intentions in eastern Zimbabwe: a cross-sectional study. Vaccines 9: 1109.
66. Runciman C, Roberts B, Alexander K, Bohler-Muller N, Bekker M, 2021. UJ/HSRC Coronavirus Democracy Survey Round 2 UJ/HSRC COVID-19 DEMOCRACY SURVEY Willingness to Take a COVID-19 Vaccine: A Research Briefing. University of Johannesburg, HSRC. Available at: https://www.researchgate.net/profile/Carin-Runciman/publication/357527591_Willingness_to_take_a_Covid-19_vaccine_A_research_briefing/links/61d2a6f7b3d95f7c4b1c7d8f/Willingness-to-take-a-Covid-19-vaccine-A-research-briefing.pdf. Accepted January 2021.
67. Oluwatemitope Olomofe C et al., Predictors of uptake of a potential COVID-19 vaccine among Nigerian adults. medRxiv. doi: 10.1101/2020.12.28.20248965.
68. Dula J et al., 2021. COVID-19 vaccine acceptability and its determinants in Mozambique: an online survey. Vaccines (Basel) 9: 828.
69. Rikitu Terefa D et al., 2021. COVID-19 vaccine uptake and associated factors among health professionals in Ethiopia. Infect Drug Resist 14: 5531–5541.
70. Alhassan RK, Owusu-Agyei S, Ansah EK, Gyapong M, 2021. COVID-19 vaccine uptake among health care workers in Ghana: a case for targeted vaccine deployment campaigns in the global south. Hum Resour Health 19: 1–12.
71. Aneampong T, Akosukorang EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH, 2021. Examining vaccine hesitancy in sub-Saharan Africa: a survey of the knowledge and attitudes among adults in COVID-19 vaccine in Nigeria. Pan Afr Med J 38: 230.
72. Ilesanmi O, Afolabi A, Uchendu O, 2021. The prospective COVID-19 vaccine: willingness to pay and perception of community members in Ibadan, Nigeria. PeerJ 9: e11153.
73. Ngasa NC, Ngasa SN, Armelle L, Tchouda S, Abanda C, 2021. Spirituality and other factors associated with COVID-19 vaccine acceptance amongst healthcare workers in Cameroon. ResearchSquare. doi:10.21203/rs.3.rs-712354/v1.
74. Belsti Y et al., 2021. Willingness of Ethiopian population to receive COVID-19 vaccine. J Multidiscip Healthc 14: 1233–1243.
75. Enläde OD, Olaranmoyo A, Otovwe A, Akintunde FE, Okekere CO, Aniyeloye AQ, 2021. Willingness to accept COVID-19 vaccine and its determinants among Nigerian citizens: a web-based cross-sectional study. J Adv Med Med Res 33: 13–22.
76. Ahmed MAM et al., 2021. COVID-19 vaccine acceptability and adherence to preventive measures in Somalia: results of an online survey. Vaccines 9: 543.
77. Kabamba Nzaj M et al., 2020. Acceptability of vaccination against COVID-19 among healthcare workers in the Democratic Republic of the Congo. Pragmat Res Obs 11: 103–109.
78. Zewude B, Habtegiorgis T, 2021. Willingness to take COVID-19 vaccine among people most at risk of exposure in southern Ethiopia. Pragmat Res Obs 12: 37–47.
79. Iljysu Z et al., 2021. “Why should I take the COVID-19 vaccine after recovering from the disease?” A mixed-methods study of correlates of COVID-19 vaccine acceptability among health workers in northern Nigeria. Pathog Glob Health 22: 1–9.
80. Mesele M, 2021. COVID-19 vaccination acceptance and its associated factors in Sodo Wolaita, southern Ethiopia: cross-sectional study. Infect Drug Resist 14: 2361–2367.
81. Shehata WM, Elshora AA, Abu-Elenin MM, 2022. Physicians’ attitudes and acceptance regarding COVID-19 vaccines: a cross-sectional study in mid Delta region of Egypt. Environ Sci Pollut Res Int 29: 15838–15848.
82. Alice Tobin E, Okonofua M, Adeke A, Obi A, 2021. Willingness to accept a COVID-19 vaccine in Nigeria: a population-based cross-sectional study. Cent Afr J Public Health 7: 53.
83. Agyeck Mw, Afirfa-Anane GF, Kyei-Arthur F, Addo B, 2021. Acceptability of COVID-19 vaccination among healthcare workers in Ghana. Adv Public Health. doi: 10.1155/2021/9998176.
84. Afolabi AA, Ilesanmi OS, 2021. Dealing with vaccine hesitancy in Africa: the prospective COVID-19 vaccine context. Pan Afr Med J 38: 1–7.
85. Choi MC, 2021. COVID-19 vaccines for low-and middle-income countries. Trans R Soc Trop Med Hyg 115: 447–456.
86. Bangalee V, Suleman F, 2020. Access considerations for a COVID-19 vaccine for South Africa. S Afr Fam Pract 62: 1–4.
87. Equroa JP et al., 2021. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet 397: 562–564.
88. Samarakereja U, 2021. Feelings towards COVID-19 vaccination in Africa. Lancet Infect Dis 21: 324.
89. Shey Wysonge C et al., 2022. Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future? Vac Immun 18: 1–3.
90. Makoni M, 2021. Tanzania refuses COVID-19 vaccines. Lancet 397: 566.
91. Betsch C, Schmid P, Heineimeier D, Korn L, Holtmann C, Böhm R, 2018. Beyond confidence: development of a
measure assessing the 5C psychological antecedents of vaccination. *PLoS One* 13: e0208801.
93. Martin LR, Petrie KJ, 2017. Understanding the dimensions of anti-vaccination attitudes: the Vaccination Attitudes Examination (VAX) scale. *Ann Behav Med* 51: 652–660.
94. Nindrea RD, Usman E, Katar Y, Sari NP, 2021. Acceptance of COVID-19 vaccination and correlated variables among global populations: a systematic review and meta-analysis. *Clin Epidemiol Glob Health* 12: 100899.
95. Wang Q, Yang L, Jin H, Lin L, 2021. Vaccination against COVID-19: a systematic review and meta-analysis of acceptability and its predictors. *Prev Med (Baltimore)* 150: 106694.
96. Bartsch SM et al., 2020. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. *Am J Prev Med* 59: 493–503.
97. Loubet P et al., 2021. Why promoting a COVID-19 vaccine booster dose? *Anaesth Crit Care Pain Med* 40: 100967.
98. Doria-Rose N et al., 2021. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. *N Engl J Med* 384: 2259–2261.
99. Levin EG et al., 2021. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. *N Engl J Med* 385: e84.
100. Ryman T, MacAuley R, Nashimirimana D, Taylor P, Shimp L, Wilkins K, 2010. Reaching every district (RED) approach to strengthen routine immunization services: evaluation in the African region, 2005. *J Public Health (Bangkok)* 32: 18–25.
101. Baltazar CS et al., 2018. Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique. *PLoS One* 13: 1–13.
102. Hummel D, Maedche A, 2019. How effective is nudging? A quantitative review on the effect sizes and limits of empirical nudging studies. *J Behav Exp Econ* 80: 47–58.
103. Iwuagwu AO, Kalu ME, 2021. A promising approach to reducing social loneliness among older adults in Nigeria during COVID-19 pandemic. *J Gerontol Soc Work* 64: 449–451.
104. Hofman KJ, Kanyengo CW, Rapp BA, Kotzin S, 2009. Mapping the health research landscape in sub-Saharan Africa: a study of trends in biomedical publications. *J Med Libr Assoc* 97: 41–44.